BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Real-time BOERSE MUENCHEN 07:17:10 30/05/2024 pm IST | ||
| 1,105 EUR | +0.74% |
|
| Current month | +7.52% | ||
| 1 month | +24.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 30/24/30 | 1,105 | +0.74% |
| 29/24/29 | 1,097 | +1.08% |
| 28/24/28 | 1,085 | -1.31% |
| 27/24/27 | 1,100 | +0.67% |
| 24/24/24 | 1,092 | +0.73% |
Real-time BOERSE MUENCHEN
Last update May 30, 2024 at 07:17 pm IST
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD3TA6 |
| ISIN | DE000HD3TA65 |
| Date issued | 18/03/2024 |
| Strike | 1,350 $ |
| Maturity | 20/12/2024 (204 Days) |
| Parity | 1 : 1 |
| Emission price | 927.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,105 € |
|---|---|
| Lowest since issue | 835 € |
| Spread | 0.13 € |
| Spread % | 0.01% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
811.5
USD
Average target price
850.8
USD
Spread / Average Target
+4.84%
- Stock Market
- Certificates
- Certificat
